Kemp Proteins — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Kemp Proteins is a private, revenue-generating contract research organization (CRO) that provides essential protein and antibody production services to biotech and pharma clients. The company leverages multiple expression platforms (mammalian, baculovirus, microbial) and a full suite of downstream and analytical capabilities to support discovery, development, and pre-GMP manufacturing. Recent strategic partnerships and a $5M growth financing round indicate an active phase of expansion and service portfolio development. Its ISO certifications and project-focused model position it as a reliable partner for complex biologics development.

AntibodiesProteomics

Technology Platform

Integrated multi-platform protein expression and antibody development services, including mammalian, baculovirus, microbial, and yeast systems, coupled with downstream purification, analytical characterization (SPR/BLI), and pre-GMP biomanufacturing up to 100L.

Opportunities

The expanding global biologics pipeline and increasing biopharma outsourcing create sustained demand for high-quality protein services.

Strategic partnerships allow for service portfolio expansion into adjacent areas like conjugation and structural biology without major capital investment.

The shift towards complex therapeutic modalities requires the specialized problem-solving expertise that Kemp offers.

Risk Factors

Revenue is project-based and susceptible to fluctuations in client R&D budgets and biotech funding cycles.

The competitive CRO/CDMO landscape pressures pricing and requires continuous differentiation.

Operational success depends on consistently solving technically challenging protein expression problems, where failures can damage client relationships and reputation.

Competitive Landscape

Kemp competes in a fragmented market with large, full-service CDMOs (e.g., Lonza, Thermo Fisher), broad-based CROs (e.g., Charles River Labs), and numerous niche protein service providers. Its differentiation lies in its focused gene-to-protein expertise, customized project approach, and mid-scale pre-GMP capabilities. Competition is based on technical success rates, turnaround time, cost, and quality of scientific collaboration.

More companies in Biologics / Biosimilars →More companies in United States →